Stock·NASDAQ·Technology
Check Point Software Technologies Ltd. (CHKP)
- Market cap
- $14.08B
- P/E
- 14.14
- Dividend yield
- 0.00%
- Street target
- $140.00median of 38 analysts
- 52-week range
- $112.23 $210.66
The short version
Where CHKP stands today, in four lines, and what CleaRank Financial AI makes of it.
CHKP at a glance
Check Point Software Technologies Ltd. (CHKP): Buy, 61/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 50-day but below its 200-day moving average ($133.16 and $142.83).
- Earnings CHKP beat estimates in 5 of its last 6 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $12.2M and made no open-market purchases over the last 18 months.
- Valuation P/E of 14.1 against 35.1 for the Technology sector: a discount to peers (-60%).
Figures as of October 17, 2026.
CleaRank Financial AI
CHKP, or Check Point Software Technologies Ltd., receives a Buy rating from CleaRank with a model score of 61/100.
Valuation contributes the most to that score: the P/E of 14.14 is 59.7% below the sector median (a discount to peers), and the P/S of 5.10 is 32.9% below the sector median. Slower revenue growth weighs on the score most, with sales up 1.30%, 22.9 percentage points behind the sector median. Trend signals are mixed, with the price 3.54% above its 50-day average of $133.16 yet 3.48% below its 200-day average of $142.83. The price fell 26.81% across the past year.
Only on CleaRank
Figures we compute ourselves from CHKP's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $137.87 is 3.5% above the 50-day simple moving average of $133.16.Price above its 200-day average ›
The price is 3.5% below the 200-day simple moving average of $142.83.50-day average above the 200-day ›
The 50-day average ($133.16) is 6.8% below the 200-day average ($142.83), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 26% of its 52-week range, between $112.23 and $210.66.
CHKP share price
Pick a period: each tab shows how far CHKP has moved over it, to the last close.
Today's trading
Where CHKP sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/4P/E below the sector median ›
The trailing P/E of 14.14 is 59.7% below the Technology median of 35.1.P/S below the sector median ›
The price-to-sales ratio of 5.10 is 32.9% below the sector median of 7.6.Profitable over the last 12 months ›
Net income over the last 12 months was $1.0B on revenue of $2.8B, a net margin of 37.9%.Beat estimates in most recent reports ›
CHKP beat the EPS estimate in 5 of its last 6 reports.
Key statistics
The headline figures for CHKP.
As of October 17, 2026, CHKP trades at $137.87, with a market value of $14.08B and a P/E ratio of 14.14.
What the numbers say
CleaRank Financial AI's reading of CHKP's valuation, growth and risks.
On earnings, CHKP is valued at 14.14 times, against a median of 35.1 for Technology: a discount to peers, with the P/E 59.7% below that median. The price-to-sales ratio of 5.10 sits 32.9% below the sector median of 7.6. CHKP has a market capitalisation of $14.1B.
CHKP's revenue growth lags the sector: sales rose 1.30% in the latest year, while the sector median is 24.2%. The company converts revenue into a net margin of 37.93% and an operating margin of 27.48%. Its return on equity of 37.64% is above the sector median of 13.4%. On the balance sheet, debt-to-equity stands at 0.72.
In its most recent available report in our data, dated April 30, 2026, CHKP reported $2.50 a share against an estimate of $2.40, a beat of 4.17%. The share price moved up 1.81% in the first session after that report.
CHKP has beaten the EPS estimate in 5 of its last 6 reports, but the share price still fell in the next session after 3 of those 5 beats. Analysts expect EPS of $10.44 for this fiscal year and $11.29 for next year. That implies a 12.2% decline for the current year.
CHKP typically moves about 2.23% in a day, based on recent volatility. The stock is 34.55% below its 52-week high of $210.66.
CHKP against the Technology sector
How CHKP compares with the median Technology stock CleaRank tracks.
Price to earnings vs sector: CHKP trades at a notable discount to sector peers (-60%), which may indicate undervaluation or specific company headwinds.
Return vs XLK: Since May 6, 2025, CHKP has lost 37.6% against a gain of 71.7% for XLK.
Performance against XLK
CHKP and the Technology sector fund over the same days.
Revenue and earnings
How much CHKP sells, and how much of it becomes profit.
Revenue growth: Revenue grew 6.3% in FY2025 to $2.7B, from $2.6B a year earlier.
Profit margin: The net margin was 38.8% in FY2025, up from 33.0% the year before.
Profitable: CHKP earned $1.1B in FY2025.
Earnings reality check
Did CHKP beat what analysts expected, and how did the stock react?
Earnings record: CHKP beat the analyst estimate in 5 of the last 6 quarters.
Market reaction: The stock fell in the first session after 3 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Apr 30, 2026after close | $2.40 | $2.50 | +4.17% | +1.81% | +2.75% |
| Oct 28, 2025after close | $2.45 | $3.94 | +60.82% | -3.09% | -5.80% |
| Jul 30, 2025after close | $2.36 | $2.37 | +0.42% | -0.25% | +0.82% |
| Apr 23, 2025after close | $2.19 | $2.21 | +0.91% | +2.26% | +7.49% |
| Jan 30, 2025after close | $2.65 | $2.70 | +1.89% | -0.44% | -2.99% |
| Oct 29, 2024after close | $2.25 | $2.25 | +0.00% | -2.24% | -3.84% |
Reports after April 30, 2026 are not yet in our data.
As of October 17, 2026, CHKP has beaten the analyst EPS estimate in 5 of its last 6 reported quarters and fell in the first trading session after 3 of those beats; its most recent report in our data, on April 30, 2026, came in 4.17% above the estimate and the stock moved +1.81% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 56.9, in neutral territory.RSI above 50 ›
An RSI of 56.9 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of CHKP
The score, the reasoning behind it, and what could move the price next.
CHKP gives a mixed trend reading. At $137.87, the stock is 3.54% above its 50-day average of $133.16, yet 3.48% below its 200-day average of $142.83. Within its 52-week range, the price is 22.85% above the low of $112.23 and 34.55% below the high of $210.66, which leaves it near the bottom of that range. The 50-day average is 6.77% below the 200-day average, so the longer-run structure has not turned up yet, even though the price has moved back above the shorter average.
Recent gains are set against a weaker record over longer periods. The price rose 0.13% over the past month and 0.56% over the past three months, yet it fell 26.81% over the past year. Last session volume was 76.6% above its average, on a day when the price slipped 0.17%. At 56.9, the 14-day RSI sits in the neutral zone, and the MACD line is positive.
Earnings beat ›
The April 30, 2026 report beat the EPS estimate by 4.17%, and the share price rose 1.81% in the first session after it.
Source: Earnings report, April 30, 2026
Rating reaffirmed ›
Wedbush kept its Neutral rating on September 11, 2026.
Source: Analyst action, Wedbush, September 11, 2026
- The two closest levels matter most: the 200-day SMA at $142.83 sits above the price, while the 20-day EMA at $134.12 sits below it.
- A 14-day RSI of 56.9 falls in the neutral zone, and the MACD line is positive. Momentum is considered stretched only when readings climb above 70 or drop below 30.
- CHKP's share price rose 1.81% in the first session after the April 30, 2026 report, and the company has beaten estimates in 5 of the last 6 reports.
CHKP's trend is mixed. The price sits above its 50-day average of $133.16 but below its 200-day average of $142.83. Closing above the 200-day would turn both signals up, while closing below the 50-day would turn both down. On the way down, the first level below the price is the 20-day EMA at $134.12, and on the way up, the first level above is the 200-day SMA at $142.83.
CHKP's 14-day RSI of 56.9 sits in the neutral zone, in the 40 to 60 band.
Technical indicators
Momentum and trend for CHKP, from its daily closes.
As of October 17, 2026, with CHKP at $137.87, its 14-day RSI is 56.9 (neutral territory), its 50-day simple moving average is $133.16 and its 200-day is $142.83.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What CHKP moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, CHKP's 1-year correlation of daily returns is +0.18 with S&P 500 (SPY), +0.12 with Nasdaq 100 (QQQ), +0.06 with Bitcoin (BTC) and +0.01 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
13 of 38 analysts rate it a buy or strong buy, 25 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $140.00 is 1.5% above the price.More buy ratings than three months ago ›
13 of 38 rate it a buy now, against 15 of 38 three months ago.
CHKP Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 11, 2026 | Wedbush | Assumes | Neutral |
| Aug 3, 2026 | Goldman Sachs | Maintains | Neutral |
| Aug 3, 2026 | Citigroup | Maintains | Neutral |
| Jul 31, 2026 | UBS | Maintains | Neutral |
| Jul 31, 2026 | Wells Fargo | Maintains | Equal-Weight |
| Jul 31, 2026 | Stifel | Maintains | Hold |
As of October 17, 2026, 38 Wall Street analysts cover CHKP: 13 rate it a buy or strong buy, 25 a hold and 0 a sell or strong sell. Their 12-month price targets range from $105.00 to $201.00, with a median of $140.00, 1.5% above the price of $137.87.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CHKP trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CHKP's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CHKP tends to move, against the market and on its own.
The long record
CHKP's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 2.23% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 51.8%, from June 2025 to April 2026; the price is still 40.9% below that peak.Most 1-year holds ended higher ›
65% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $18,093, against $42,055 in the S&P 500 (SPY).
CHKP Drawdowns & Recovery
As of October 17, 2026, CHKP's worst peak-to-trough fall over the last 10 years with dividends reinvested was -51.8% (June 2025 to April 2026); it is still 40.9% below that peak, and 65% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CHKP in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CHKP trailed the S&P 500 over this period: $18,093 against $42,055.
A $10,000 investment in CHKP in October 2016 would be worth about $18,093 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CHKP, and which have not.
Strongest month, July: an average of +5.03%, up in 8 of 10 years.
Weakest month, November: an average of -1.77%, up in 5 of 10 years.
This month, October: has averaged +1.66%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CHKP's strongest calendar month has been July (average +5.03%, up in 8 of 10 years) and its weakest November (average -1.77%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CHKP, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CHKP today could grow to about $18,266 by 2036 in the base case, with a 90th-percentile outcome near $54,869 and a 10th-percentile outcome around $6,081. Projections are statistical simulations, not guarantees.
CHKP Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $175 for CHKP by 2030 in the base case, from $138 today (1.3x over 4 years). The 10th-percentile path ends near $87.50. These are outcomes of a Monte Carlo simulation run on CHKP's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $103 | $146 | $207 | |
| 2028 | $95.10 | $156 | $254 | |
| 2029 | $90.43 | $165 | $302 | |
| 2030 | $87.50 | $175 | $352 | |
| 2031 | $85.61 | $186 | $406 |
Method: a lognormal simulation of CHKP's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
CHKP insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought CHKP shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 17, 2026, CHKP insiders reported 6 open-market sales worth $12.2M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Yoav Chelouche
Director
|
Grant | 1.1K | - |
| Sep 2, 2026 | Dafna Eyal Gruber
Director
|
Grant | 1.1K | - |
| Sep 2, 2026 | Tzipi Ozer-Armon
Director
|
Grant | 1.1K | - |
| Sep 2, 2026 | Tal Shenhav Shavit
Director
|
Grant | 1.1K | - |
| Sep 2, 2026 | Jill D Smith
Director
|
Grant | 1.1K | - |
| Sep 2, 2026 | Jerry T Ungerman
Director
|
Grant | 1.1K | - |
| Sep 2, 2026 | Nadav Zafrir
Chief Executive Officer
|
Grant | 44.8K | - |
| Aug 4, 2026 | Sherif Seddik
Officer
|
Sell | 10.3K | $1.3M |
| Aug 3, 2026 | Roei Golan
Chief Financial Officer
|
Sell | 9.9K | $1.2M |
| Aug 3, 2026 | Nataly Kremer
Officer
|
Sell | 665 | $82.2K |
| Jul 27, 2026 | Roei Golan
Chief Financial Officer
|
Grant | 282 | - |
| Jul 10, 2026 | Sherif Seddik
Officer
|
Grant | 6.1K | - |
| Jun 11, 2026 | Tal Shenhav Shavit
Director
|
Sell | 25.0K | $3.1M |
| Jun 11, 2026 | Jerry T Ungerman
Director
|
Sell | 25.0K | $3.1M |
| Jun 11, 2026 | Tal Shenhav Shavit
Director
|
Option | 25.0K | $2.9M |
| Jun 11, 2026 | Jerry T Ungerman
Director
|
Option | 25.0K | $2.9M |
| Jun 2, 2026 | Yoav Chelouche
Director
|
Sell | 25.0K | $3.5M |
| Jun 2, 2026 | Yoav Chelouche
Director
|
Option | 25.0K | $2.9M |
| May 26, 2026 | Gil Shwed
Director and Beneficial Owner of more than 10% of a Class of Security
|
Grant | 3.0K | - |
| May 8, 2026 | Nataly Kremer
Officer
|
Grant | 658 | - |
Source: TwelveData, from reported insider filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.